Ad hoc announcement pursuant to Art. 53 LR Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care

Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials.“Since 40% of people with DLBCL relapse after initial therapy, achieving meaningful treatment effects in the front-line setting has the potential to be transformative,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This Polivy regimen is the first in two decades to improve progression-free survival in DLBCL compared to the standard of care, and we look forward to sharing these results with health authorities to bring this important potential new treatment option to patients as soon as possible.”Today ’s POLARIX results will be presented at an upcoming medical meeting and submitted to health authorities as part of Roche’s commitment to transforming the treatment of DLBCL by providing options tailored to patient and healthcare professional needs. Roche w...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Many public health experts were opposed to a boosters-for-all approach. The new variant is changing some minds.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Coronavirus Omicron Variant Vaccination and Immunization Immune System Coronavirus (2019-nCoV) Disease Rates Third World and Developing Countries United States Source Type: news
Much remains unknown about the new variant of the coronavirus. Experts had said it was only a matter of time before the variant showed up in the United States.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Coronavirus Omicron Variant Coronavirus (2019-nCoV) Vaccination and Immunization Source Type: news
Men with localized prostate cancer who opt for surgery instead of surveillance are more than twice as likely to regret their decision.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
RefleXion Medical's biology-guided radiotherapy has received a breakthroug...Read more on AuntMinnie.comRelated Reading: RefleXion to showcase tech, abstracts at ASTRO 2021 Lantheus, RefleXion to collaborate on prostate cancer treatment RefleXion to install X1 at cancer center in Texas RefleXion raises another $40M, mulls Asia strategy RefleXion, Telix partner on high-risk cancer treatments
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
The agency said it was “issuing this directive to prevent the importation and spread of a communicable disease of public health importance,” an apparent reference to the new Omicron variant.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Coronavirus (2019-nCoV) Airlines and Airplanes Coronavirus Omicron Variant Centers for Disease Control and Prevention Delta Air Lines Inc United States Africa United Airlines Source Type: news
One of the four women who say they were “groomed” for sex by Ghislaine Maxwell testified Wednesday that effrey Epstein took her to meet Trump #effreyepstein #jeffreyepstein #ghislainemaxwell #accuser #trumpone
Source: Reuters: Health - Category: Consumer Health News Source Type: news
Omicron has arrived in the United States, but its effects on the scope of the COVID-19 pandemic remain unknown, experts said Wednesday.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Academia | Allergy & Immunology | Belgium Health | Biotechnology | Cancer | Cancer & Oncology | Diabetes | Eloxatin | Endocrinology | Food and Drug Administration (FDA) | France Health | Hodgkin's Disease | Infectious Diseases | International Medicine & Public Health | Internet | Israel Health | Japan Health | Leukemia | Lymphoma | Men | Middle East Health | Molecular Biology | Non-Hodgkin's Lymphoma | Opthalmology | Partnerships | Pharmaceuticals | Portugal Health | Prednisone | Primary CNS Lymphoma | Rituxan | Science | Study | Switzerland Health | Treanda | USA Health | WHO